Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
Identifieur interne : 007321 ( Main/Exploration ); précédent : 007320; suivant : 007322Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
Auteurs : J A Rizzo [Brésil] ; C. Belo ; R. Lins ; G. DreyerSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 2007.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Animaux, Antihelminthiques (effets indésirables), Antihelminthiques (usage thérapeutique), Association de médicaments, Brésil (épidémiologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Enfant, Femelle, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Mâle, Prévalence, Résultat thérapeutique, Wuchereria bancrofti.
- MESH :
- effets indésirables : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filaricides.
- parasitologie : Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filaricides.
- épidémiologie : Brésil, Filariose lymphatique.
- Adolescent, Adulte, Animaux, Association de médicaments, Enfant, Femelle, Humains, Mâle, Prévalence, Résultat thérapeutique, Wuchereria bancrofti.
- Wicri :
- geographic : Brésil.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (adverse effects), Albendazole (therapeutic use), Animals, Anthelmintics (adverse effects), Anthelmintics (therapeutic use), Brazil (epidemiology), Child, Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (parasitology), Female, Filaricides (adverse effects), Filaricides (therapeutic use), Humans, Male, Prevalence, Treatment Outcome, Wuchereria bancrofti.
- MESH :
- chemical , adverse effects : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : Brazil.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- parasitology : Elephantiasis, Filarial.
- Adolescent, Adult, Animals, Child, Drug Therapy, Combination, Female, Humans, Male, Prevalence, Treatment Outcome, Wuchereria bancrofti.
Abstract
In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.
DOI: 10.1179/136485907X176517
PubMed: 17550648
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003627
- to stream PubMed, to step Curation: 003627
- to stream PubMed, to step Checkpoint: 003627
- to stream Ncbi, to step Merge: 002750
- to stream Ncbi, to step Curation: 002750
- to stream Ncbi, to step Checkpoint: 002750
- to stream Main, to step Merge: 007467
- to stream Main, to step Curation: 007321
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.</title><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name><affiliation wicri:level="2"><nlm:affiliation>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE</wicri:regionArea><placeName><region type="state">Pernambuco</region></placeName></affiliation></author><author><name sortKey="Belo, C" sort="Belo, C" uniqKey="Belo C" first="C" last="Belo">C. Belo</name></author><author><name sortKey="Lins, R" sort="Lins, R" uniqKey="Lins R" first="R" last="Lins">R. Lins</name></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17550648</idno><idno type="pmid">17550648</idno><idno type="doi">10.1179/136485907X176517</idno><idno type="wicri:Area/PubMed/Corpus">003627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003627</idno><idno type="wicri:Area/PubMed/Curation">003627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003627</idno><idno type="wicri:Area/PubMed/Checkpoint">003627</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003627</idno><idno type="wicri:Area/Ncbi/Merge">002750</idno><idno type="wicri:Area/Ncbi/Curation">002750</idno><idno type="wicri:Area/Ncbi/Checkpoint">002750</idno><idno type="wicri:doubleKey">0003-4983:2007:Rizzo J:children:and:adolescents</idno><idno type="wicri:Area/Main/Merge">007467</idno><idno type="wicri:Area/Main/Curation">007321</idno><idno type="wicri:Area/Main/Exploration">007321</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.</title><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name><affiliation wicri:level="2"><nlm:affiliation>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE</wicri:regionArea><placeName><region type="state">Pernambuco</region></placeName></affiliation></author><author><name sortKey="Belo, C" sort="Belo, C" uniqKey="Belo C" first="C" last="Belo">C. Belo</name></author><author><name sortKey="Lins, R" sort="Lins, R" uniqKey="Lins R" first="R" last="Lins">R. Lins</name></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="ISSN">0003-4983</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (adverse effects)</term><term>Anthelmintics (therapeutic use)</term><term>Brazil (epidemiology)</term><term>Child</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Antihelminthiques (effets indésirables)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Association de médicaments</term><term>Brésil (épidémiologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Mâle</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Brazil</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Brésil</term><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Association de médicaments</term><term>Enfant</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Brésil</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.</div></front></TEI><affiliations><list><country><li>Brésil</li></country><region><li>Pernambuco</li></region></list><tree><noCountry><name sortKey="Belo, C" sort="Belo, C" uniqKey="Belo C" first="C" last="Belo">C. Belo</name><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name><name sortKey="Lins, R" sort="Lins, R" uniqKey="Lins R" first="R" last="Lins">R. Lins</name></noCountry><country name="Brésil"><region name="Pernambuco"><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007321 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007321 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17550648
|texte= Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17550648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |